Prestige Consumer Healthcare (PBH) Cash & Current Investments (2010 - 2025)
Prestige Consumer Healthcare (PBH) recorded quarterly Cash & Current Investments of $62.4 million in Q4 2025, down 47.63% quarter-over-quarter from $119.1 million in Q3 2025, and up 22.6% on a YoY basis from $50.9 million in Q4 2024.
Prestige Consumer Healthcare (PBH) Cash & Current Investments (2010 - 2025) Analysis & Trends
Prestige Consumer Healthcare's Cash & Current Investments history runs 16 years deep, the most recent figure standing at $62.4 million for Q4 2025.
- In Q4 2025, Cash & Current Investments rose 22.6% year-over-year to $62.4 million; the TTM figure through Dec 2025 stood at $62.4 million (up 22.6% YoY), while the FY2025 annual figure was $97.9 million, up 110.64% from the prior year.
- Cash & Current Investments was $62.4 million for Q4 2025 at Prestige Consumer Healthcare, down from $119.1 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $163.6 million in Q2 2021 to a low of $21.0 million in Q4 2021.
- Historically, Cash & Current Investments has averaged $64.5 million across 5 years, with a median of $53.1 million in 2023.
- Biggest YoY gain for Cash & Current Investments was 310.88% in 2022; the steepest drop was 78.08% in 2022.
- A 5-year view of Cash & Current Investments shows it stood at $21.0 million in 2021, then surged by 310.88% to $86.4 million in 2022, then declined by 26.34% to $63.6 million in 2023, then fell by 20.03% to $50.9 million in 2024, then advanced by 22.6% to $62.4 million in 2025.
- The last three Cash & Current Investments figures came in at $62.4 million (Q4 2025), $119.1 million (Q3 2025), and $139.5 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | 3.74 Bn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | 1.94 Bn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | 2.15 Bn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | 77.77 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | 1.32 Bn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | 428.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | 511.86 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | 498.58 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | 750.88 Mn |
| 10 | Prestige Consumer Healthcare | 2.39 Bn | 2.33 Bn | 157.37 Mn | 62.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 62.37 Mn |
| Sep 30, 2025 | 119.11 Mn |
| Jun 30, 2025 | 139.50 Mn |
| Mar 31, 2025 | 97.88 Mn |
| Dec 31, 2024 | 50.87 Mn |
| Sep 30, 2024 | 51.54 Mn |
| Jun 30, 2024 | 34.26 Mn |
| Mar 31, 2024 | 46.47 Mn |
| Dec 31, 2023 | 63.62 Mn |
| Sep 30, 2023 | 60.07 Mn |
| Jun 30, 2023 | 54.58 Mn |
| Mar 31, 2023 | 58.49 Mn |
| Dec 31, 2022 | 86.36 Mn |
| Sep 30, 2022 | 42.44 Mn |
| Jun 30, 2022 | 35.87 Mn |
| Mar 31, 2022 | 27.19 Mn |
| Dec 31, 2021 | 21.02 Mn |
| Sep 30, 2021 | 42.82 Mn |
| Jun 30, 2021 | 163.62 Mn |
| Mar 31, 2021 | 32.30 Mn |